Lupus Market Research Report- Forecast till 2027

Lupus Market Research Report by Type (Systemic Lupus Erythematosus, Neonatal Lupus, Others), Treatment (NSAIDS, Corticosteroid, Antimalarial Drug, Biologics, Other), End User (Hospital & Clinics, Diagnostic Laboratories, Others), and Region-Forecast till 2027

ID: MRFR/Pharma/5173-HCR | February 2021 | Region: Global | 90 pages

Lupus Market Scenario


The Lupus Market is expected to grow significantly over the forecast period. It is anticipated that the lupus market held a market value of USD 1.48 billion in 2017 and is projected to grow at a CAGR of 11.2% over the forecast period. Lupus is a systemic autoimmune disease that causes inflammation throughout the body.  In patients with lupus, the immune system attacks healthy cells and tissues of the body which can result in damage to many parts of the body including the skin, joints, kidney, heart, lungs, blood vessels, and brain. The factors such as the rising prevalence of lupus, ongoing medical advancements in the treatment of systemic lupus erythematosus, increasing research and development activities are expected to drive lupus market growth during the forecast period. According to the Lupus Foundation of America, about 1.5 million Americans have a form of lupus, and about 16,000 new cases are reported each year in the Americas. Despite the drivers, the factors such as strict government regulation and increasing prices of lupus drugs may hamper the market growth over the assessment period.


Currently, a large number of companies are present in the lupus market. The prominent market players are involved in the development of new products and product launches. For instance, in July 2017, GlaxoSmithKline received FDA approval for a new self-injectable formulation of Benlysta for the treatment of adult patients with systemic lupus erythematosus.  


Segmentation


The Lupus Market has been segmented into types, treatment, and end user. The global market, on the basis of type, has been segmented into systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus. The systemic lupus erythematosus segment is expected to hold the largest market share owing to the growing prevalence and increasing drug development in recent years.


On the basis of treatment, the market has been segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, corticosteroids, immunosuppressants, biologics, and other.


On the basis of end user, the market has been segmented into hospital & clinics, diagnostic laboratories, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The lupus market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European lupus market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The lupus market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The lupus market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key Players


Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Merck KGaA, and Eli Lily and Company are some of the key players in the global lupus market.


Regional Market Summary


Global Lupus Market Share (%), by Region, 2017
Global Lupus Market Share (%), by Region, 2017


Source: White Papers, Company Presentations, Annual Reports


Geographically, the Americas is anticipated to dominate the lupus market owing to the rising demand for better treatment options, growing prevalence of lupus, government initiatives for lupus, and availability of reimbursement. Additionally, the developed healthcare infrastructure and accessibility to biologics are expected to contribute to the market growth in the region.


Europe is expected to hold the second largest position in the lupus market. The market growth in this region is attributed to the rising number of research and development activities and the increasing prevalence of lupus in the region.


The lupus market in the Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of lupus, continuously growing healthcare sector and increasing regional expansion by prominent market players. According to the Australian Society of Clinical Immunology and Allergy, in 2016, it was estimated that lupus affected more than 20,000 people in Australia and New Zealand.


The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Lupus Market, by Technique



  • Systemic Lupus Erythematosus

  • Cutaneous Lupus Erythematosus

  • Drug-Induced Lupus Erythematosus

  • Neonatal Lupus


Lupus Market, by Product



  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

  • Antimalarial Drugs

  • Corticosteroids

  • Immunosuppressants

  • Biologics

  • Others


Lupus Market, by End User



  • Hospital & Clinics

  • Diagnostic Laboratories

  • Others


Lupus Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • South America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • JapanChina

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Research and consulting firmsPharmaceutical and biotechnology manufacturers

  • Contract research organizations (CROs)

  • Contract manufacturing organizations (CMOs)



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2017: USD 1.48 Billion
  • 2027: Significant Value
  •   CAGR   11.2% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Types, Treatment, and End user
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Merck KGaA, and Eli Lily and Company
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Rising prevalence of lupus
  • Ongoing medical advancements in the treatment of systemic lupus erythematosus
  • Increasing research and development activities


  • Frequently Asked Questions (FAQ) :


    The lupus market is projected to grow at 11.2% CAGR between 2020-2027.

    The Americas is projected to command the largest share in the lupus market.

    Growing prevalence of lupus and rising R&D activities are boosting market growth.

    High cost of lupus drugs may limit market growth.

    Different strategies used by market players to create a dominance in the lupus market include mergers, acquisitions, collaborations, and product developments.

    Table of Contents

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Lupus Market, by Type

    6.1 Introduction

    6.2 Systemic Lupus Erythematosus

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Cutaneous Lupus Erythematosus

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4 Drug-Induced Lupus Erythematosus

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.5 Neonatal lupus

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7. Global Lupus Market, by Treatment

    7.1 Introduction

    7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 Antimalarial Drugs

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.4 Corticosteroids

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.5 Immunosuppressants

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.6 Biologics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.7 Others

    Chapter 8. Global Lupus Market, by End User

    8.1 Introduction

    8.2 Hospital & Clinics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.3 Diagnostic Laboratories

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4 Others

    Chapter 9. Global Lupus Market, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 South Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 Middle East

    9.5.2 Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    Chapter 11. Company Profiles

    11.1 Aurinia Pharmaceuticals Inc.

    11.1.1 Company Overview

    11.1.2 Treatment Overview

    11.1.3 Financials Overview

    11.1.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Bristol-Myers Squibb Company

    11.2.1 Company Overview

    11.2.2 Treatment Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Cadila Healthcare

    11.3.1 Company Overview

    11.3.2 Treatment Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 GlaxoSmithKline plc

    11.4.1 Company Overview

    11.4.2 Treatment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Mylan N.V.

    11.5.1 Company Overview

    11.5.2 Treatment Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 F. Hoffmann-La Roche AG

    11.6.1 Company Overview

    11.6.2 Treatment Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Pfizer, Inc.

    11.7.1 Overview

    11.7.2 Treatment Overview

    11.7.3 Financial Overview

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Sanofi

    11.8.1 Overview

    11.8.2 Treatment Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 Lycera Corporation

    11.9.1 Overview

    11.9.2 Treatment Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.10 Merck KGaA

    11.10.1 Overview

    11.10.2 Treatment Overview

    11.10.3 Financials

    11.10.4 Key Developments

    11.10.5 SWOT Analysis

    11.11 Eli Lily and Company

    11.11.1 Overview

    11.11.2 Treatment Overview

    11.11.3 Financials

    11.11.4 Key Developments

    11.11.5 SWOT Analysis

    11.12 Others

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s Viewpoint

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Predictions for the Lupus Industry

    Chapter 13. Appendix

    LIST OF TABLES

    Table 1 Global Lupus Market Synopsis, 2020–2027

    Table 2 Global Lupus Market Estimates and Forecast, 2020–2027

    (USD Million)

    Table 3 Global Lupus Market, by Region, 2020–2027 (USD Million)

    Table 4 Global Lupus Market, by Type, 2020–2027 (USD Million)

    Table 5 Global Lupus Market, by Treatment, 2020–2027 (USD Million)

    Table 6 Global Lupus Market, by End User, 2020–2027 (USD Million)

    Table 7 North America: Lupus Market, by Type, 2020–2027 (USD Million)

    Table 8 North America: Lupus Market, by Treatment, 2020–2027 (USD Million)

    Table 9 North America: Lupus Market, by End User, 2020–2027 (USD Million)

    Table 10 US: Lupus Market, by Type, 2020–2027 (USD Million)

    Table 11 US: Lupus Market, by Treatment, 2020–2027 (USD Million)

    Table 12 US: Lupus Market, by End User, 2020–2027 (USD Million)

    Table 13 Canada: Lupus Market, by Type, 2020–2027 (USD Million)

    Table 14 Canada: Lupus Market, by Treatment, 2020–2027 (USD Million)

    Table 15 Canada: Lupus Market, by End User, 2020–2027 (USD Million)

    Table 16 South America: Lupus Market, by Type, 2020–2027

    (USD Million)

    Table 17 South America: Lupus Market, by Treatment, 2020–2027

    (USD Million)

    Table 18 South America: Lupus Market, by End User, 2020–2027

    (USD Million)

    Table 19 Europe: Lupus Market, by Type, 2020–2027 (USD Million)

    Table 20 Europe: Lupus Market, by Treatment, 2020–2027 (USD Million)


    Table 21 Europe: Lupus Market, by End User, 2020–2027 (USD Million)

    Table 22 Western Europe: Lupus Market, by Type, 2020–2027 (USD Million)

    Table 23 Western Europe: Lupus Market, by Treatment, 2020–2027 (USD Million)

    Table 24 Western Europe: Lupus Market, by End User, 2020–2027 (USD Million)

    Table 25 Eastern Europe: Lupus Market, by Type, 2020–2027 (USD Million)

    Table 26 Eastern Europe: Lupus Market, by Treatment, 2020–2027 (USD Million)

    Table 27 Eastern Europe: Lupus Market, by End User, 2020–2027 (USD Million)

    Table 28 Asia-Pacific: Lupus Market, by Type, 2020–2027 (USD Million)

    Table 29 Asia-Pacific: Lupus Market, by Treatment, 2020–2027

    (USD Million)

    Table 30 Asia-Pacific: Lupus Market, by End User, 2020–2027 (USD

    Million)

    Table 31 Middle East & Africa: Lupus Market, by Type, 2020–2027 (USD Million)

    Table 32 Middle East & Africa: Lupus Market, by Treatment, 2020–2027 (USD Million)

    Table 33 Middle East & Africa: Lupus Market, by End User, 2020–2027 (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Lupus Market

    Figure 3 Segmentation Market Dynamics for Global Lupus Market

    Figure 4 Global Lupus Market Share, by Type, 2020

    Figure 5 Global Lupus Market Share, by Treatment, 2020

    Figure 6 Global Lupus Market Share, by End User, 2020

    Figure 7 Global Lupus Market Share, by Region, 2020

    Figure 8 North America: Lupus Market Share, by Country, 2020

    Figure 9 Europe: Lupus Market Share, by Country, 2020

    Figure 10 Asia-Pacific: Lupus Market Share, by Country, 2020

    Figure 11 Middle East & Africa: Lupus Market Share, by Country, 201

    Figure 12 Global Lupus Market: Company Share Analysis, 2020 (%)

    Figure 13 Aurinia Pharmaceuticals Inc.: Key Financials

    Figure 14 Aurinia Pharmaceuticals Inc.: Segmental Revenue

    Figure 15 Aurinia Pharmaceuticals Inc.: Geographical Revenue

    Figure 16 Bristol-Myers Squibb Company: Key Financials

    Figure 17 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 18 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 19 Cadila Healthcare: Key Financials

    Figure 20 Cadila Healthcare: Segmental Revenue

    Figure 21 Cadila Healthcare: Geographical Revenue

    Figure 22 GlaxoSmithKline plc : Key Financials

    Figure 23 GlaxoSmithKline plc: Segmental Revenue

    Figure 24 GlaxoSmithKline plc : Geographical Revenue

    Figure 25 Mylan N.V: Key Financials

    Figure 26 Mylan N.V: Segmental Revenue

    Figure 27 Mylan N.V. Geographical Revenue

    Figure 28 F. Hoffmann-La Roche AG: Key Financials

    Figure 29 F. Hoffmann-La Roche AG: Segmental Revenue

    Figure 30 F. Hoffmann-La Roche AG: Geographical Revenue

    Figure 31 Pfizer, Inc.: Key Financials

    Figure 32 Pfizer, Inc.: Segmental Revenue

    Figure 33 Pfizer, Inc.: Geographical Revenue

    Figure 34 Sanofi: Key Financials

    Figure 35 Sanofi: Segmental Revenue

    Figure 36 Sanofi: Geographical Revenue

    Figure 37 Lycera Corporation: Key Financials

    Figure 38 Lycera Corporation: Segmental Revenue

    Figure 39 Lycera Corporation: Geographical Revenue

    Figure 40 Merck KGaA: Key Financials

    Figure 41 Merck KGaA : Segmental Revenue

    Figure 42 Merck KGaA: Geographical Revenue

    Figure 43 Eli Lily and Company: Key Financials

    Figure 44 Eli Lily and Company: Segmental Revenue

    Figure 45 Eli Lily and Company: Geographical Revenue

    Figure 46 Norgen Biotek Corp.: Key Financials

    Figure 47 Norgen Biotek Corp.: Segmental Revenue

    Figure 48 Norgen Biotek Corp.: Geographical Revenue